医疗设备统治es
这Indian healthcare industry has been growing at double-digit rates and has evolved significantly in the last decade. However, a number of challenges need to be addressed in providing access to quality, affordable healthcare in the country. The new medical device rules which came into force from January 2018 has finally given the medical devices andin-vitro diagnostic devices(IVD) industry a distinctive regulatory identity. By delinking devices from drugs, the multitudes of devices used in the country today, from the humble to the complex have potential to come under the ambit of rules to ensure patient safety, quality and performance parameters of devices sold within the country.
虽然目前的法规仍然是对毒品和化妆品法，1940年, the Parliamentary Standing Committee for Health and Family Welfare has actively sought comments and concerns to revive the bill for a stand-alone legislation for medical devices, which has been under discussion for a couple of years now. Widely anticipated to be tabled in the Parliament this year, the singular act of medical devices, if passed, will host India’s regulatory framework for the sector on par with mature global economies.
通过在作品中进行分阶段的方法，当前形式中的规则为实施而赋予了新产品的范围。几年后，预计该法规将涵盖整个MedTech设备和该国制造的IVD。然而，立法的成功取决于该行业所表达的一些实施瓶颈。
这obstacles to successful implementation of the regulation:
创建正确的生态系统：
实施的主要关注点是建立通知机构的生态系统，这将承担评估监管合规性的负担。到目前为止，该过程没有预期的速度。
这State Vs. The Center Debate:
像药品的姊妹行业一样，中央政府制定的任何立法的疗效都取决于州政府的参与和合作。
这present legislation is based on the licensing model with a one-time audit and no in-built surveillance mechanism to measure continued compliance. Sampling is also expected to be conducted by the central licensing authority (这Central Drugs Standard Control Organization）或各个国家许可机构（国家Food and Drug Administrations) themselves.
如果这是实施立法的正确方法，那么利益相关者仍在进行持续的辩论，因为这与世界上任何其他监管模式不同。这医疗设备CE标记例如，在每年进行严格的监视之后，获得了认可的第三方组织的惊喜检查和审核，以确保无党派的审核。
- Infrastructure Issues:
这“Make in India”计划刺激了全国各地的Medtech公园的建立，并承诺以土地分配和补贴的形式支持政府支持，以鼓励国内Medtech行业的发展。但是，这些公园的基础设施发展的速度相对较慢，这使国内产业从设置商店推迟。面对预计大型玩家作为价格控制的影响，这可能会对该国的设备的可用性产生更大的影响。
- 行业意识：
国内MedTech景观虽然由大型参与者和跨国公司主导，但还包括中小型玩家和初创公司争夺大型市场份额。尽管这些玩家对法规和合规要求有鸟眼的看法，但对规则的总体缺乏深入的理解。
This creates a problem – the scope of the regulation is automatically limited to the 22 device types that were already under mandatory control. To advance further to higher levels of manufacturing, domestic players must comprehend the scope of requirements in Schedule 4 and 5, which pertain to the manufacturing of medium to high-risk devices.
Possible solutions
克服政策不确定性：
这new医疗装置rules被构建的目的是使国内工业与全球制造实践相提并论。
While the policy has the right intended for addressing multiple aspects of this paradigm shift – encouraging domestic manufacturers, boosting innovation and R&D (research and development), the industry is looking for an assurance on follow-through at the basic level. For instance, fixing land allocation and electricity connections, and a clarity on the exact subsidies provided at medtech parks.
Another aspect is to streamline the licensing process to ensure that manufacturers who already possess reputed international certifications can obtain the Indian mark easily. Currently, a domestic manufacturer with a CE mark must undergo nearly the same regulatory grind as a new manufacturer, a rather discouraging measure.
修改“印度制造”：
Medical electronics is slated as a critical aspect of the new manufacturing policy for electronics, expected to be released in 2018. Both the industry and the government should work together to clear implementation bottlenecks to ensure they reap the benefits of the policy.
促进初创公司：
这healthcare startups have gained tremendous private equity and venture capital attention over the past year and this trend are expected to intensify in the coming years.
另一方面,医学技术创业公司面临的乐趣ding crunch unless the solutions they provide are unique and innovative. In the interest of promoting domestic manufacturing and bridging the accessibility-affordability gap, the state governments should set-up schemes to fund the medtech startups.
Conclusion
With the ‘Digital India’ and ‘Make in India’ initiatives, along with multiple other positive policies and regulatory reforms that have been introduced in the recent past, it is clear that India’s evolution will benefit all industries, including the digital health and medical device industries. In the coming year, a lot of development in both spaces is expected. All stakeholders, from patients to manufacturers, are eagerly hoping that the healthcare revolution continues its momentum in the coming year. With multiple reforms in the pipeline, 2018 promises to be an exciting time for both the digital health and medical device sectors in India.
